The local administration of Islamabad has decided to administer polio vaccine to the children who have come from different parts of the country along with their parents to participate in the sit-ins.
Minister of State for Capital Administration and Development Division (CADD) Barrister Usman Ibrahim has directed the Pakistan Institute of Medical Sciences (Pims), the National Institute of Rehabilitation Medicine (Nirm) and Polyclinic to make special arrangements to vaccinate the children.
“Children do not belong to any party, they are the children of Pakistan, so the government is responsible for their healthcare,” he said.“Our teams would go to the sit-in venue and administer the polio vaccine to children,” the minister said. He requested the parents sitting there to cooperate with the polio teams.
Vice Chancellor of Pims Prof Javed Akram while talking to Dawn said 30 per cent children in the sit-ins belonged to Khyber Pakhtunkhwa and Federally Administered Tribal Areas (Fata) so there was a possibility that they might carry the poliovirus.
“Moreover, in the absence of proper hand-washing facility and sewerage system, the chances of transfer of virus increased,” he said.
After the vaccination, certificates will be issued to the children, he said.
The Rand Corporation updated a 2011 Institute of Medicine consensus report on vaccine safety (National Academies Press 2011). To do so, they performed a systematic review of evidence published from 2010 to August 2013. Of 20,478 possible articles, 67 met inclusion criteria. The combined data revealed the following:
Concerning adverse events associated with vaccines:
Hepatitis A vaccine: Moderate evidence of an association with immune thrombocytopenic purpura (ITP) only in older children (age 7–17 years).
MMR (measles, mumps and rubella) vaccine: Strong evidence of an association with febrile seizure. Moderate evidence of an association with ITP.
Pneumococcal (PCV13) vaccine: Moderate evidence of an association with febrile seizure (estimated rates for infants aged 16 months, 13.7 per 100,000 doses for PCV13 alone and 45 per 100,000 for PVC13 combined with influenza trivalent inactivated vaccine).
Rotavirus vaccine: Moderate evidence of an association with intussusception (estimated rate, 1–5 cases per 100,000 doses).
Equally important: What is not associated with vaccines:
High-quality evidence that MMR vaccine is not associated with autism.
No vaccines studied were associated with childhood leukemia.
Moderate evidence that DTaP (diphtheria, tetanus, and acellular pertussis) vaccine is not associated with diabetes mellitus and hepatitis B vaccination is not associated with multiple sclerosis.
Moderate evidence that Hib (Haemophilus influenza type b) vaccine is not associated with serious adverse events.
This study should reassure everyone that vaccines are safe, that adverse events are rare, and in most cases will resolve completely. Transparency about adverse events may provide reassurance of the benefit of immunizations. If these data do not reassure parents, at least clinicians can speak with confidence of the safety and importance of vaccines for the health of children.
Preparing for school is the perfect time to make sure children are up to date on their vaccines. Getting all of the recommended vaccines is one of the most important things parents can do to protect their children’s health.
When children are not vaccinated, they are at increased risk for disease and can spread disease to others in their classroom and community – including babies who are too young to be fully vaccinated, and people with weakened immune systems due to cancer and other health conditions. Schools are highly susceptible to outbreaks of infectious diseases because students can easily transmit illnesses to one another as a result of poor hand washing, uncovered coughs and dense populations.
Influenza poses unique risks to pregnant women, who are particularly susceptible to morbidity and mortality. Historically, pregnant women have been overrepresented among patients with severe illness and complications from influenza, and have been more likely to require hospitalization and intensive care unit admission.
An increased risk of adverse outcomes is also present for fetuses/neonates born to women affected by influenza during pregnancy. These risks to mothers and babies have been observed during both nonpandemic and pandemic influenza seasons.
During the H1N1 influenza pandemic of 2009-2010, pregnant women were more likely to be hospitalized or admitted to intensive care units, and were at higher risk of death compared to nonpregnant adults.
Vaccination remains the most effective intervention to prevent severe illness, and antiviral medications are an important adjunct to ameliorate disease when it occurs. Unfortunately, despite national guidelines recommending universal vaccination for women who are pregnant during influenza season, actual vaccination rates do not achieve desired targets among pregnant women.
Pregnant women are also sometimes reluctant to use antiviral medications during pregnancy. Some of the barriers to use of vaccines and medications during pregnancy are a lack of knowledge of recommendations and of safety data. By improving knowledge and understanding of influenza and vaccination recommendations, vaccine acceptance rates among pregnant women can be improved.
Currently, the appropriate use of vaccination and antiviral medications is the best line of defense against influenza and its sequelae among pregnant women, and strategies to increase acceptance are crucial. This article will review the importance of influenza in pregnancy, and discuss vaccination and antiviral medications for pregnant women.
Hepatitis A is a contagious liver disease that results from infection with the hepatitis A virus. It can range in severity from a mild illness lasting a few weeks to a serious illness lasting several months. Hepatitis A cases have decreased by more than 90% over the past 20 years, but there are still approximately 20,000 new cases of hepatitis A each year. Fortunately, vaccination can help prevent this disease.
A new study finds a high-dose flu vaccine provides better protection among people 65 and older than a standard flu shot. Dr. Susan Rehm of Cleveland Clinic, did not take part in the study, but discusses the findings.